10:11 AM
 | 
Mar 16, 2018
 |  BC Week In Review  |  Clinical News  |  Regulatory

FDA places hold on Advaxis' combo trial

Advaxis Inc. (NASDAQ:ADXS) said FDA placed a clinical hold on a Phase I/II trial of axalimogene filolisbac (ADXS11-001) in combination with PD-L1 inhibitor Imfinzi durvalumab to treat HPV-related cancers.

According to the company, the hold is related to a patient death reported on Feb. 27...

Read the full 201 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >